UPC rejects Alexion’s rehearing bid in spat with Amgen and Samsung

Court sets strict rules on rehearing's, saying "only fundamental procedural defects can be the basis for a rehearing” | Follows UK blow to Alexion, allowing biosimilars onto market.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

UK court clears the way for Amgen and Samsung to launch biosimilars

22 May 2025 AstraZeneca subsidiary Alexion suffers setback in bid to stop rivals launching biosimilars of blood disorder drug | Ruling concerns an error in original patent application | Decision follows UPC defeat for Alexion over eculizumab patent.

Big Pharma

AstraZeneca unit faces class-action suit over alleged Soliris monopoly

17 April 2025 Massachusetts lawsuit claims subsidiary of UK pharma company unlawfully re-patented eculizumab, resulting in overpayments of more than $2 billion.

Europe

Life sciences cases at the UPC will surely rise, but is the court prepared?

18 June 2024 Signs show that an uptick of life sciences cases at the Unified Patent Court is likely, but does the court have capacity? Anna Leathley, Richard Newell & Sarah Mitchell of Carpmaels & Ransford explore.

More on this story

Europe

UK court clears the way for Amgen and Samsung to launch biosimilars

Big Pharma

AstraZeneca unit faces class-action suit over alleged Soliris monopoly

17 April 2025 Massachusetts lawsuit claims subsidiary of UK pharma company unlawfully re-patented eculizumab, resulting in overpayments of more than $2 billion.

Europe

Life sciences cases at the UPC will surely rise, but is the court prepared?

More on this story

Europe

UK court clears the way for Amgen and Samsung to launch biosimilars

Big Pharma

AstraZeneca unit faces class-action suit over alleged Soliris monopoly

17 April 2025 Massachusetts lawsuit claims subsidiary of UK pharma company unlawfully re-patented eculizumab, resulting in overpayments of more than $2 billion.

Europe

Life sciences cases at the UPC will surely rise, but is the court prepared?